AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27513901
Drug: PGA monotherapy
RxNorm normalized name: PGA
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGA monotherapy
Trial: 27513901
Drug: PGA combination
RxNorm normalized name: PGA
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGA combination regimens
Trial: 27513901
Drug: Non-PGA medications
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PGA medications
Trial: 27513901
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (not on any topical medications)
Trial: 24962242
Drug: PGB-CR 330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB-CR 330 mg
Trial: 24962242
Drug: PGB-CR 165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB-CR 165 mg
Trial: 16043801
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d ethyl‐EPA
Trial: 10457698
Drug: Office-based vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vision therapy with supplementary home therapy
Trial: 10457698
Drug: Home therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home therapy only
Trial: 34185
Drug: Propranolol (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (daily doses increasing up to 3 g)
Trial: 34185
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean therapeutic level of 1600 mg/day)
Trial: 34185
Drug: Propranolol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (dose increase related to hypertensive encephalopathy)
Trial: 26819451
Drug: R-CHOP treatment
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP treatment in ABC patients
Trial: 24332997
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 325mg daily for 6 weeks
Trial: 23067321
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg once daily for 12 weeks
Trial: 11530128
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg continuously during four 28-day cycles) + Medroxyprogesterone acetate (10 mg), Norethindrone acetate (1 mg), or Placebo (last 14 days of each cycle)
Trial: 11530128
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg continuously during four 28-day cycles) + Medroxyprogesterone acetate (10 mg), Norethindrone acetate (1 mg)
Trial: 15481766
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C (ephedrine 20 mg and caffeine 200 mg) in hypertensive patients treated with antihypertensive agents other than beta-blockers
Trial: 15481766
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in hypertensive patients under any antihypertensive treatment
Trial: 8302451
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium naproxen (550 mg) immediately after induction of anesthesia (Group I)
Trial: 8302451
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium naproxen (550 mg) at the end of surgery (Group II)
Trial: 8302451
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline immediately after induction of anesthesia (Group III)
Trial: 3327697
Drug: Intravenous nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nifedipine infusion
Trial: 3327697
Drug: Intravenous nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nifedipine infusion with additional propranolol
Trial: 27492789
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylphenidate (MPH)
Trial: 29229652
Drug: Individualised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised treatment by general practitioners based on pathophysiological phenotyping and individualised treatment goals.
Trial: 29229652
Drug: Individualised lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised lifestyle intervention (web-based and face-to-face) to improve daily physical activity and dietary changes.
Trial: 16966110
Drug: Acupuncture (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (three outpatient treatments with eight needles applied to bilateral points LI4, SP6, UB31, and UB32)
Trial: 8774286
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg three times per day for > or = 3 days)
Trial: 26281857
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Group Therapy (ACT-G)
Trial: 24911421
Drug: Problem-solving intervention
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving intervention (PSI) consisting of 2 home visits and 18 telephone calls over a 3-month intensive intervention and a 9-month maintenance period. Both groups received monthly information letters in addition to usual care.
Trial: 24911421
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving usual care and monthly information letters.
Trial: 19851115
Drug: elvitegravir/r (150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elvitegravir/r (150/100 mg once daily) plus maraviroc (150 mg twice daily)
Trial: 19851115
Drug: maraviroc (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maraviroc (150 mg twice daily) before or after elvitegravir/r (150/100 mg once daily)
Trial: 19851115
Drug: elvitegravir/r (150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elvitegravir/r (150/100 mg once daily)
Trial: 18021205
Drug: TCA 33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCA 33% solution
Trial: 16027889
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy (cell suspension from immature nervous and hemopoietic tissues injected into the subarachnoidal space)
Trial: 12370107
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg finasteride/day
Trial: 12370107
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride/day
Trial: 15248876
Drug: IMZ implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMZ implants
Trial: 1315825
Drug: Candoxatril 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 10 mg
Trial: 1315825
Drug: Candoxatril 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 50 mg
Trial: 28799232
Drug: Professionally administered
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professionally administered plaque removal (PAPR) and photodynamic therapy (PDT)
Trial: 19803579
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy (3 individual sessions)
Trial: 8243858
Drug: Simvastatin (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10‐20 mg/day)
Trial: 3896661
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 10% clotrimazole cream
Trial: 3896661
Drug: Twice-daily application
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily application of 2% clotrimazole cream for 3 days
Trial: 25031188
Drug: Low-dose thiazide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thiazide diuretics (12.5 mg/day of hydrochlorothiazide)
Trial: 25031188
Drug: No thiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thiazide diuretics
Trial: 18570306
Drug: DUAL 1500
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DUAL 1500 (1500 mg R1626 bid + peginterferon alfa‐2a)
Trial: 18570306
Drug: DUAL 3000
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DUAL 3000 (3000 mg R1626 bid + peginterferon alfa‐2a)
Trial: 18570306
Drug: TRIPLE 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa‐2a + ribavirin)
Trial: 16029797
Drug: 2.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 Gy fraction (total dose 15.0 Gy)
Trial: 16029797
Drug: 5.0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 Gy fraction (total dose 30.0 Gy)
Trial: 11925390
Drug: Thyrotrophin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotrophin-releasing hormone (TRH) infusion
Trial: 11925390
Drug: Dopaminergic type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic type 2 (DA2) receptor blockade
Trial: 2205571
Drug: Xylocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylocaine (1 mg/kg iv)
Trial: 7430412
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate capsules
Trial: 7430412
Drug: Enteric-coated erythromycin
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated erythromycin base tablets
Trial: 28232972
Drug: V-shaped toothbrush
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V-shaped toothbrush (Oral-B Ortho)
Trial: 26005776
Drug: Atorvastatin (20mg/day)
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20mg/day)
Trial: 23942231
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (specific study)
Trial: 21336838
Drug: CHO mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO mouth rinse (25 ml)
Trial: 17192510
Drug: Innovator 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator 0.005% latanoprost ophthalmic solution
Trial: 17192510
Drug: Cyclodextrin-containing latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclodextrin-containing latanoprost ophthalmic solution
Trial: 15149259
Drug: Intergroup competition
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intergroup competition (combination of competition and cooperation)
Trial: 2730278
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) administered intravenously
Trial: 31559634
Drug: Topiramate 50-100
RxNorm normalized name: topiramate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 50-100 mg/day to week 36
Trial: 25344375
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 mcg/d, N=80)
Trial: 25226738
Drug: Natural honey
RxNorm normalized name: Robitussin Cough Drop Herbal With Natural Honey Center
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural honey (70 g daily for 4 weeks)
Trial: 18817597
Drug: Supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised treatment (10 mg amodiaquine/kg and 4 mg artesunate/kg daily for 3 days, directly observed in hospital)
Trial: 18817597
Drug: Unsupervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised treatment (first dose supervised, remaining doses taken at home)
Trial: 10747828
Drug: trovafloxacin 200
RxNorm normalized name: trovafloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trovafloxacin 200 mg od
Trial: 9484878
Drug: ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 500 mg bd
Trial: 10747828
Drug: lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lomefloxacin 400 mg od
Trial: 1893812
Drug: verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 80 mg orally every 6 hr for 10 doses
Trial: 1893812
Drug: diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem 60 mg by mouth as one dose
Trial: 7065521
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum concentration of theophylline (20 mg/L)
Trial: 7065521
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum concentration of theophylline (10 mg/L)
Trial: 28353600
Drug: Gum-chewing (sugarless
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum-chewing (sugarless gum, 3 times daily for at least 15 minutes until postoperative exhaust defecation)
Trial: 19656025
Drug: Full-mouth ultrasonic
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth ultrasonic debridement + amoxicillin and metronidazole
Trial: 14739186
Drug: Recombinant follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle stimulating hormone
Trial: 14739186
Drug: Electrocautery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone
Trial: 9129894
Drug: 15,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15,000 IU of heparin (group A)
Trial: 9129894
Drug: 100 IU.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU.kg‐1 of heparin (group B)
Trial: 7961027
Drug: Thermoradiotherapy (HTRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoradiotherapy (HTRT) with regional hyperthermia and radiotherapy, total dose ranged from 42 to 80 Gy (mean 62.9 Gy) for definitive treatment, and 38 to 47 Gy (mean 40.6 Gy) for preoperative cases. Radiofrequency capacitive hyperthermia was administered twice weekly, with total sessions ranging from 5 to 16 (mean 9.0) for definitive treatment and 3 to 8 (mean 6.7) for preoperative cases.
Trial: 31959233
Drug: Lifestyle physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle physical activity group (LPAG) aiming to increase daily physical activity and reduce sedentary behaviour for 12 weeks
Trial: 29358714
Drug: Disulfiram treatment
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram treatment in AD model mice
Trial: 29358714
Drug: Disulfiram treatment
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram treatment in SH-SY5Y human neuronal cells
Trial: 29358714
Drug: Disulfiram treatment
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram treatment in alcohol-dependent patients
Trial: 24572041
Drug: Lupin kernel
RxNorm normalized name: palm kernelate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupin kernel fiber (LF) 25-g/d
Trial: 20107202
Drug: LRPT 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRPT 50 mg
Trial: 20107202
Drug: LRPT 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRPT 600 mg
Trial: 17352635
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (7 joules/2 min) over the carpal tunnel area, 41 patients
Trial: 17352635
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy, 40 patients
Trial: 9810742
Drug: Experimental design
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental design (e.g. randomized clinical trial)
Trial: 7824087
Drug: Erythromycin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3.5 mg/kg bolus injection)
Trial: 3277488
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate ointment (100 mg tid)
Trial: 29925328
Drug: Gabapentin oral
RxNorm normalized name: gabapentin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin oral solution (5 mg/kg in 5 ml strawberry juice)
Trial: 29925328
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml of oral strawberry juice)
Trial: 18768528
Drug: Subcutaneous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Trial: 18768528
Drug: Intravenous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bortezomib (1.3 mg/m2, days 1, 4, 8, 11; eight 21‐day cycles)
Trial: 20613670
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day for 6 months
Trial: 11930704
Drug: Inhaled Beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Beclomethasone dipropionate (BDP) 200 micrograms/d
Trial: 11930704
Drug: Inhaled Beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Beclomethasone dipropionate (BDP) 400 micrograms/d
Trial: 3345619
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg alprazolam plus saline infusion
Trial: 3345619
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg alprazolam plus saline
Trial: 3345619
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg plus 72 micrograms alprazolam/hr for a total dose of 1.576 mg in 8 hours
Trial: 3345619
Drug: Placebo (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50% propylene glycol injection followed by saline infusion)
Trial: 30638420
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of commercial pasteurized orange juice for 2 months
Trial: 12580655
Drug: Ribose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose supplementation (32 g, 4 x 8-g doses)
Trial: 18320520
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravitreal bevacizumab
Trial: 18662829
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravitreal triamcinolone
Trial: 26210303
Drug: Active tVNS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tVNS (daily active stimulation of the left auricle for 26 weeks)
Trial: 26210303
Drug: Sham tVNS
RxNorm normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tVNS (daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation)
Trial: 22024002
Drug: Another SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another SSRI + cognitive behavior therapy (CBT)
Trial: 19729392
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE)-based therapies
Trial: 17664205
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg x kg(‐1) bolus prior to sternotomy, followed by 1 mg x kg(‐1) x hr(‐1) infusion)
Trial: 8215672
Drug: Direct infusion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct infusion
Trial: 9683306
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg day(-1))
Trial: 9683306
Drug: Norethisterone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone (2.5 mg day(-1) for 21 days out of 28 for three cycles)
Trial: 18157412
Drug: GIK infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIK infusion
Trial: 3387033
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone and high-dose metoclopramide (regimen A)
Trial: 3387033
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone and sulpiride (regimen B)